Approved for use through 01/31/2008, ONIS 0851-0031
U.S. Patient and Trademark Office, U.S. DePARTIMENT OF COMMERCE
Under the Papernick Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Offis bontriol number.

INFORMATION DISCI	LOSURE
STATEMENT BY APP	LICANT
(Not for submission under 37	7 CFR 1.99)

	Application Number Filing Date		10642937
			2003-08-18
	First Named Inventor	Binh 1	Γ. Nguyen
	Art Unit		3714
	Examiner Name	Jasso	n H. Yoo
	Attorney Docket Number		IGT1P280/P-836

				U.S.	PATENTS		Remove	
Examiner Cite Number Kind Code Issue Date Name of Patentee or Ap				Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevent Figures Appear			
	1	5489103		1996-02-06	Okamoto			
	2	5768382		1998-06-16	Schneier et al.			
If you wish	to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relev Figures Appear		
	1	20020010025		2002-01-24	Kelly et al.			
	2	20020052229		2002-05-02	Halliburton et al.			
	3	20030064771		2003-04-03	Morrow et al.			
	4	20040224773		2004-11-11	Sham			
If you wish	n to ac	l dd additional U.S. Publis	hed Ap	plication citatio	n information please click the Ad-	d button	Add	
				FORFIGN PAT	TENT DOCUMENTS		Remove	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10642937		
Filing Date		2003-08-18		
First Named Inventor Binh		f. Nguyen		
Art Unit		3714		
Examiner Name	Jasso	n H. Yoo		
Attorney Docket Number		IGT1P280/P-836		

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							
If you wisl	h to a	dd additional Foreign	Patent Docume	ent citation	information p	please click the Add butto	n Add	
			NON-PAT	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Cite Initials* Cite Initials* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishers					Ţŝ			
1 "Non-Final Office Action" from U.S. Patent Application No. 10642-934," dated February 22, 2007, 15 pages.								
If you wis	h to a	dd additional non-pate	ent literature do	cument cit	tation informa	tion please click the Add	button Add	_
				EXAMINE	R SIGNATUR	RE		
Examiner	Signs	ature				Date Considered		

E

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 2 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10642937		
Filing Date			2003-08-18		
	First Named Inventor	Binh 1	Binh T. Nguyen		
Art Unit			3714		
	Examiner Name	Jasso	n H. Yoo		
	Attorney Docket Number		IGT1P280/P-836		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 27 CER 1 07(e)/1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(10).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	Signature	/RMahboubian/	Date (YYYY-MM-DD)	2007-06-18
ı	Name/Print	Ramin Mahhouhian	Registration Number	44890

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING YESP IEEE SING COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.